Stock listing

BOATS:ALKS Alkermes plc Stock

US listing (BOATS) of Alkermes plc · home listing NASDAQ:ALKS

Follow Alkermes plc into a list and get an email when it puts out news.

Home listing price · NASDAQ:ALKS

$44.94 USD -1.91 (-4.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ALKS

Past year +59.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$44.83 – $46.89 USDNov 20, 2026
Volume
1.07M sharesNov 20, 2026
Market cap
$7.55B USDAt the close on Nov 20, 2026 · price × 168.0M shares outstanding
52-week range
$27.00 – $55.67 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$82.79M USDMedian day 1.64M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Alkermes plc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALKS · Home$44.94 USD-1.91 (-4.1%)1,070,769$45.79$46.89$44.83$46.85Close on Nov 20, 2026
Frankfurt:8AK€41.48 EUR-0.18 (-0.4%)—€40.54€41.48€40.54€41.66Close on Nov 20, 2026
Munich:8AK€41.51 EUR-1.48 (-3.4%)—€41.96€41.96€41.51€42.99Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALKS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$44.94-1.91-4.1%$45.79$46.89$44.831,070,769
$46.85+1.40+3.1%$45.26$47.06$45.251,394,840
$45.45-1.08-2.3%$46.37$46.65$45.10932,614
$46.53-0.50-1.1%$47.02$47.76$46.261,051,956
$47.03+0.05+0.1%$46.83$47.44$46.101,429,845
$46.98-0.91-1.9%$46.00$48.30$45.273,125,379
$47.89+1.42+3.1%$46.47$48.00$46.081,031,712
$46.47+0.30+0.6%$45.67$46.57$45.351,035,989
$46.17+0.27+0.6%$45.96$47.07$45.651,708,119
$45.90+1.36+3.1%$44.19$45.94$44.071,650,400
$44.54-1.35-2.9%$45.96$46.55$44.421,943,981
$45.89+0.20+0.4%$46.23$47.01$44.582,164,906
$45.69+0.80+1.8%$46.17$47.43$45.222,328,578
$44.89-0.45-1.0%$45.59$45.92$44.492,155,778
$45.34-0.03-0.1%$46.05$46.35$44.781,103,100
$45.37+0.12+0.3%$46.01$46.38$45.181,424,102
$45.25+0.93+2.1%$43.66$45.29$43.451,439,609
$44.32-0.12-0.3%$44.34$45.02$43.991,322,006
$44.44+0.81+1.9%$44.11$44.84$43.601,176,591
$43.63-0.55-1.2%$44.15$44.15$43.15884,392
$44.18+0.70+1.6%$44.00$44.68$43.461,833,975
$43.48-0.63-1.4%$44.12$44.58$43.441,781,814
$44.11+1.14+2.7%$43.38$45.19$43.212,154,017
$42.97+1.75+4.2%$41.46$43.64$41.352,713,432
$41.22+1.12+2.8%$40.18$41.57$39.713,408,302
$40.10+1.02+2.6%$39.74$40.74$39.421,976,642
$39.08-0.65-1.6%$39.59$40.65$38.981,551,180
$39.73-0.53-1.3%$40.26$40.35$39.671,068,300
$40.26-0.35-0.9%$40.67$40.87$40.002,240,200
$40.61+0.50+1.2%$40.18$40.87$39.991,627,000
$40.11-1.34-3.2%$41.10$41.26$39.113,251,000
$41.45-0.20-0.5%$41.28$42.06$41.171,816,000
$41.65-1.11-2.6%$42.64$42.71$41.241,546,000
$42.76+1.01+2.4%$42.07$43.22$41.673,125,200
$41.75+1.21+3.0%$41.03$41.96$40.322,423,500
$40.54+0.020.0%$40.00$41.41$39.992,625,700
$40.52-0.28-0.7%$40.94$40.94$39.922,527,200
$40.80+0.65+1.6%$39.84$40.90$39.842,686,800
$40.15-0.70-1.7%$40.71$40.97$40.042,356,200
$40.85+0.06+0.1%$40.94$41.12$40.492,588,000
$40.79-1.34-3.2%$42.55$42.55$40.592,843,400
$42.13-1.16-2.7%$43.20$43.62$41.232,475,700
$43.29-0.89-2.0%$44.39$44.53$43.082,310,700
$44.18+0.79+1.8%$44.27$44.79$43.113,731,100
$43.39-3.32-7.1%$46.51$46.53$43.276,935,802
$46.71+0.64+1.4%$47.10$47.40$46.411,423,600
$46.07+0.04+0.1%$46.64$47.26$45.791,854,600
$46.03+0.20+0.4%$45.73$46.14$44.632,151,200
$45.83-0.14-0.3%$46.60$46.60$45.662,029,500
$45.97-0.14-0.3%$46.75$46.75$45.731,283,100
$46.11+0.71+1.6%$44.98$46.11$44.751,193,900
$45.40-0.09-0.2%$45.24$45.61$44.721,442,800
$45.49-0.61-1.3%$45.20$46.53$44.631,355,800
$46.10-0.78-1.7%$46.14$46.93$45.801,064,000
$46.88-0.84-1.8%$48.01$48.29$46.71974,500
$47.72+0.52+1.1%$47.70$48.74$46.681,566,400
$47.20+0.21+0.4%$47.00$47.34$46.651,351,300
$46.99-0.42-0.9%$47.25$47.56$46.461,440,900
$47.41-1.49-3.0%$48.82$48.82$47.251,429,200
$48.90-0.26-0.5%$48.72$49.33$48.102,119,400
$49.16-0.05-0.1%$49.23$49.35$48.46660,900
$49.21+0.34+0.7%$48.94$49.58$48.871,127,442
$48.87+0.54+1.1%$48.05$49.03$47.641,296,669
$48.33+0.31+0.6%$48.05$48.67$47.33939,600
$48.02-2.16-4.3%$49.37$49.86$47.931,635,200

Splits

1 split · NASDAQ:ALKS · every price before a split is adjusted for it

DayRatioWhat
2-for-1Split
Ticker
BOATS:ALKS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Alkermes plc news

Alkermes plc on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 251 in all · newest Nov 5, 2026 · oldest 2019
Calls
27 calls with a replay · 27 with a transcript · latest Nov 3, 2026
Decks
73 decks · latest Nov 3, 2026

Where Alkermes plc is listed

ListingExchangeCountryCurrency
NASDAQ:ALKS · Home listingNASDAQUnited StatesUSD
LS Exchange:A1JKVHLS ExchangeGermanyEUR
Lang & Schwarz:A1JKVHLang & SchwarzGermanyEUR
BOATS:ALKS · This pageBOATSUnited StatesUSD
Frankfurt:8AKFrankfurtGermanyEUR
Tradegate:8AKTradegateGermanyEUR
Munich:8AKMunichGermanyEUR
Stuttgart:8AKStuttgartGermanyEUR
Xetra:8AKXetraGermanyEUR
Dusseldorf:8AKDusseldorfGermanyEUR

Valuation

EV/sales 4.7× against a median of 34.9×: the lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$8.31B USD
P/E
Loss
EV/sales
4.7×
EV/EBITDA
57.3×
Price/book
4.0×
Gross margin
82.9%
Operating margin
3.7%
Net margin
−0.0%
Debt to equity
0.8×
Beta vs S&P 500
0.80

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Alkermes plc · NASDAQ:ALKSUS$7.55BUS$8.31Bn/a4.7×57.3×4.0×−0.0%0.8×0.80
Vaxcyte, Inc. · NASDAQ:PCVXUS$8.77BUS$7.70Bn/an/an/a3.5×n/a0.1×1.24
Praxis Precision Medicines, Inc. · NASDAQ:PRAXUS$8.40BUS$7.65Bn/an/an/a6.7×n/a0.0×1.45
Summit Therapeutics Inc. · NASDAQ:SMMTUS$7.96BUS$7.33Bn/an/an/a14.1×n/a0.0×1.91
Protagonist Therapeutics, Inc. · NASDAQ:PTGXUS$7.92BUS$7.13B23.1×12.9×22.0×7.3×62.0%0.0×0.93
CG Oncology, Inc. · NASDAQ:CGONUS$7.10BUS$6.12Bn/a992×n/a7.2×n/a0.0×0.83
Cytokinetics, Incorporated · NASDAQ:CYTKUS$7.07BUS$6.36Bn/a56.2×n/an/a−686.6%n/a0.93
Axsome Therapeutics, Inc. · NASDAQ:AXSMUS$6.80BUS$6.68Bn/a7.7×n/a64.5×−18.2%1.8×0.69
Akeso, Inc. · HKEX:9926US$6.66BUS$6.04Bn/a13.5×n/a5.2×−36.4%0.6×n/a
Immunovant, Inc. · NASDAQ:IMVTUS$6.57BUS$5.85Bn/a825×n/a10.0×n/a0.0×1.46
Oruka Therapeutics, Inc. · NASDAQ:ORKAUS$6.50BUS$5.58Bn/an/an/a5.4×n/a0.0×1.30
Median of the othersUS$7.09BUS$6.52B23.1×34.9×22.0×7.2×−27.3%0.0×1.24

Forecasts

12 strong buy · 3 buy · 4 hold · 1 sell · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
57.74 USD · Analysts' mean
EPS, year to Dec 2026
1.55 · 4 analysts
Revenue, year to Dec 2026
1.82B · 18 analysts

Team and board

Officers

OfficerRole
Blair C. JacksonChief Executive Officer
Joshua ReedChief Financial Officer
Anne GiovanoniSenior Vice President, Corporate Counsel and Secretary
David GaffinExecutive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary
Jamie ConstantineInvestor Relations
Sandy CoombsInvestor Relations
Bhaskar RegeSenior Vice President, Discovery Medicine & Pharmaceutical Sciences
Craig HopkinsonExecutive Vice President, Research & Development and Chief Medical Officer
Declan O’ConnorSenior Vice President, Operations and Environment, Health and Safety (EHS)
Drew SansoneSenior Vice President, Regulatory Affairs
James SchoenerSenior Vice President, Business Development and Alliance Management
Julie Lekstrom HimesSenior Vice President, Clinical Development
Kanchan RelwaniSenior Vice President, Medical Affairs
Peter NormanSenior Vice President, Policy, Government & Community Relations
Stephen SchiavoSenior Vice President, Chief Human Resources Officer
Todd NicholsSenior Vice President, Chief Commercial Officer
Tom SkoffSenior Vice President, Chief Information Officer

Board

DirectorRole
Richard F. PopsDirector
Shane M. CookeChairperson
Andy Wilson
Anne C. WhitakerDirector
Blair C. JacksonChief Executive Officer
Brian P. McKeonDirector
Cato T. LaurencinDirector
Christopher I. Wright M.D.Director
Nancy L. SnydermanDirector
Nancy S. LurkerDirector
Richard B. GaynorDirector

Events

Calls

CallWhenStatus
Alkermes (NASDAQ:ALKS) Q3 2026 Earnings CallTue, Nov 03, 2026 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2026 Earnings CallTue, Jul 28, 2026 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2026 Earnings CallTue, May 05, 2026 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q4 2026 Earnings CallWed, Feb 25, 2026 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2025 Earnings CallTue, Oct 28, 2025 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2025 Earnings CallTue, Jul 29, 2025 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2025 Earnings CallThu, May 01, 2025 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2024 Earnings CallThu, Oct 24, 2024 · 8:00 PM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2024 Earnings CallWed, Jul 24, 2024 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2024 Earnings CallWed, May 01, 2024 · 8:00 AM ETReplay
All 27 calls
CallWhenStatus
Alkermes (NASDAQ:ALKS) Q4 2024 Earnings CallThu, Feb 15, 2024 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q4 2023 Earnings CallThu, Feb 15, 2024 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2023 Earnings CallWed, Oct 25, 2023 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2023 Earnings CallWed, Jul 26, 2023 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2023 Earnings CallWed, Apr 26, 2023 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q4 2022 Earnings CallThu, Feb 16, 2023 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2022 Earnings CallWed, Nov 02, 2022 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2022 Earnings CallWed, Jul 27, 2022 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2022 Earnings CallWed, Apr 27, 2022 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q4 2021 Earnings CallWed, Feb 16, 2022 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2021 Earnings CallWed, Oct 27, 2021 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2021 Earnings CallWed, Jul 28, 2021 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2021 Earnings CallWed, Apr 28, 2021 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q4 2020 Earnings CallThu, Feb 11, 2021 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q3 2020 Earnings CallThu, Oct 29, 2020 · 8:30 AM ETReplay
Alkermes (NASDAQ:ALKS) Q2 2020 Earnings CallWed, Jul 29, 2020 · 8:00 AM ETReplay
Alkermes (NASDAQ:ALKS) Q1 2020 Earnings CallWed, Apr 29, 2020 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 3, 2026 · Before open+1.8%
Q2 2026Jul 28, 2026 · Before open−4.2%
Q1 2026May 5, 2026 · Before open+6.1%
Q4 2025Feb 25, 2026−8.0%
Q3 2025Oct 28, 2025 · Before open+4.3%
Q2 2025Jul 29, 2025 · Before open+3.3%
Q1 2025May 1, 2025 · Before open+6.3%
Q4 2024Feb 12, 2025 · Before open+4.8%
Q3 2024Oct 24, 2024 · Before open−3.6%
Q2 2024Jul 24, 2024 · Before open+6.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 1, 2024 · Before open−2.2%
Q4 2023Feb 15, 2024 · Before open+16.3%
Q3 2023Oct 25, 2023 · Before open−7.4%
Q2 2023Jul 26, 2023 · Before open−2.6%
Q1 2023Apr 26, 2023 · Before open−7.0%
Q4 2022Feb 16, 2023 · Before open+4.4%
Q3 2022Nov 2, 2022 · Before open+3.5%
Q2 2022Jul 27, 2022 · Before open−5.3%
Q1 2022Apr 27, 2022 · Before open+11.9%
Q4 2021Feb 16, 2022 · Before open+14.9%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings16 slidesNov 3, 2026
Q2 2026 Earnings PresentationEarnings16 slidesJul 28, 2026
SLEEP 2026Conference19 slidesJun 17, 2026
Q1 2026 Earnings PresentationEarnings16 slidesMay 5, 2026
Q4 2026 Earnings PresentationEarnings19 slidesFeb 25, 2026
Investor Presentation (January 2026)Investor deck29 slidesJan 12, 2026
Technical Presentation (November 2025)Technical15 slidesNov 12, 2025
Q3 2025 Earnings PresentationEarnings16 slidesOct 28, 2025
Merger or Acquisition (October 2025)Merger or acquisition13 slidesOct 22, 2025
Technical Presentation (September 2025)Technical58 slidesSep 8, 2025
Show 50 decks
DeckKindSlidesDate
Technical Presentation (September 2025)Technical34 slidesSep 8, 2025
Q2 2025 Earnings PresentationEarnings16 slidesJul 29, 2025
Q1 2025 Earnings PresentationEarnings16 slidesMay 1, 2025
Q4 2024 Earnings PresentationEarnings21 slidesFeb 12, 2025
43rd Annual J.P. Morgan Healthcare Conference (January 2025)Conference25 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck26 slidesDec 2, 2024
Q3 2024 Earnings PresentationEarnings19 slidesOct 24, 2024
Technical Presentation (October 2024)Technical85 slidesOct 9, 2024
Q2 2024 Earnings PresentationEarnings19 slidesJul 24, 2024
Q1 2024 Earnings PresentationEarnings23 slidesMay 1, 2024
Q1 2024 Earnings PresentationEarnings13 slidesMay 1, 2024
Q4 2023 Earnings PresentationEarnings26 slidesFeb 15, 2024
Q4 2024 Earnings PresentationEarnings21 slidesFeb 15, 2024
42nd Annual J.P. Morgan Healthcare Conference 2024Conference29 slidesJan 8, 2024
42nd Annual J.P. Morgan Healthcare Conference 2024Conference28 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck28 slidesNov 15, 2023
Q3 2023 Earnings PresentationEarnings27 slidesOct 25, 2023
Technical Presentation (October 2023)Technical16 slidesOct 23, 2023
Q2 2023 Earnings PresentationEarnings17 slidesJul 26, 2023
Proxy Contest (June 2023)Proxy contest17 slidesJun 26, 2023
Proxy Contest (June 2023)Proxy contest41 slidesJun 15, 2023
Proxy Contest (June 2023)Proxy contest36 slidesJun 9, 2023
Proxy Contest (June 2023)Proxy contest56 slidesJun 7, 2023
Proxy Contest (June 2023)Proxy contest95 slidesJun 6, 2023
Q1 2023 Earnings PresentationEarnings21 slidesApr 26, 2023
Q4 2022 Earnings PresentationEarnings24 slidesFeb 16, 2023
41st Annual J.P. Morgan Healthcare Conference 2023Conference28 slidesJan 9, 2023
Q3 2022 Earnings PresentationEarnings22 slidesNov 2, 2022
Q2 2022 Earnings PresentationEarnings15 slidesJul 27, 2022
Q1 2022 Earnings PresentationEarnings16 slidesApr 27, 2022
Q4 2021 Earnings PresentationEarnings18 slidesFeb 16, 2022
40th Annual J.P. Morgan Healthcare Conference 2022Conference35 slidesJan 11, 2022
Q3 2021 Earnings PresentationEarnings11 slidesOct 27, 2021
Q2 2021 Earnings PresentationEarnings13 slidesJul 28, 2021
Q1 2021 Earnings PresentationEarnings13 slidesApr 28, 2021
Investor Day (March 2021)Investor day144 slidesMar 25, 2021
Q4 2020 Earnings PresentationEarnings15 slidesFeb 11, 2021
39th Annual J.P. Morgan Healthcare Conference 2021Conference35 slidesJan 11, 2021
Q3 2020 Earnings PresentationEarnings12 slidesOct 29, 2020
Q2 2020 Earnings PresentationEarnings14 slidesJul 29, 2020

This page holds 50 of 73 decks. Open Decks

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.48B1.56B1.66B1.11B1.17B1.04B1.17B1.09B903.4M745.7M
Cost of revenue196.5M245.3M253.0M218.1M197.3M178.3M180.4M176.4M154.7M132.1M
Gross profit1.28B1.31B1.41B893.7M976.4M860.4M990.6M917.9M748.6M613.6M
Research and development324.0M245.3M270.8M272.7M290.9M394.6M512.8M425.4M412.9M387.1M
Selling, general and administrative701.5M645.2M689.8M590.8M549.6M538.8M599.4M526.4M421.6M374.1M
Operating income254.0M420.6M414.1M-6.09M97.7M-112.4M-175.5M-99.1M-147.9M-208.7M
Depreciation and amortization27.2M28.5M74.9M77.9M78.7M81.9M80.4M103.7M98.5M94.3M
EBITDA281.1M449.2M489.0M71.8M176.4M-30.6M-95.1M4.53M-49.4M-114.4M
Interest expense12.3M22.6M23.0M13.0M11.2M8.66M13.6M15.4M12.0M14.9M
Income before tax291.4M443.8M421.5M-31.1M87.7M-96.5M-197.1M-127.0M-143.3M-214.4M
Income tax49.8M71.6M-97.6M2.02M11.3M14.3M-436.0K12.3M14.7M-5.94M
Net income241.7M367.1M355.8M-158.3M-48.2M-110.9M-196.6M-139.3M-157.9M-208.4M
Earnings per share, basic1.472.222.14-0.97-0.30-0.70-1.25-0.90-1.03-1.38
Earnings per share, diluted1.432.172.10-0.97-0.29-0.70-1.25-0.90-1.03-1.38

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents388.6M291.1M457.5M292.5M337.5M273.0M203.8M266.8M191.3M186.4M
Short-term investments199.6M460.5M316.0M316.0M198.8M362.1M331.2M272.5M242.2M310.9M
Receivables334.0M384.5M332.5M288.0M313.2M275.1M257.1M292.2M233.6M191.1M
Inventory196.6M182.9M186.4M181.4M150.3M125.7M101.8M90.2M93.3M63.0M
Current assets1.93B1.42B1.49B1.13B1.06B1.11B962.0M983.3M808.8M790.7M
Property, plant and equipment221.7M227.6M226.9M222.9M341.1M350.0M362.2M310.0M284.7M264.8M
Goodwill83.0M83.0M83.0M83.0M92.9M92.9M92.9M92.9M92.9M92.9M
Total assets2.49B2.06B2.14B1.96B2.02B1.95B1.81B1.83B1.80B1.73B
Accounts payable108.0M45.6M65.6M32.8M55.7M46.0M54.3M39.8M55.5M46.3M
Current liabilities543.4M465.2M520.2M497.7M471.3M438.3M391.1M339.8M291.1M212.0M
Long-term debt0287.7M290.3M292.8M272.1M274.3M276.5M278.4M280.7M
Total debt075.5M290.7M293.3M295.8M275.0M277.1M279.3M281.4M283.7M
Total liabilities667.7M590.6M933.5M920.2M911.9M882.7M720.0M653.7M594.4M516.9M
Shareholders' equity1.82B1.46B1.20B1.04B1.11B1.07B1.09B1.17B1.20B1.21B
Shares outstanding165.6M162.2M167.0M164.4M161.9M159.2M157.8M155.8M154.0M152.4M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations520.8M439.1M401.4M21.0M101.7M82.8M72.1M99.3M19.2M-63.8M
Capital spending-40.4M-33.5M-48.0M-38.3M-28.0M-42.2M-90.9M-69.4M-51.3M-43.7M
Free cash flow480.3M405.6M353.3M-17.2M73.7M40.6M-18.9M29.9M-32.1M-107.5M
Cash from investing295.5M-111.3M53.4M-64.5M-66.2M-11.5M-141.8M-22.2M-18.4M127.2M
Cash from financing12.4M-494.1M-289.7M-1.57M29.1M-2.17M6.76M-1.62M4.08M-58.2M
Dividends paid-1.43M-8.75M-672.0K-9.61M00
Share buybacks-31.0M-200.3M-28.5M-18.2M-16.6M-7.70M-9.32M-19.6M-16.4M-13.5M
Change in cash828.6M-166.3M165.0M-45.1M64.6M69.2M-63.0M75.5M4.92M5.27M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 12, 2026Material contractSEC
4 · Change in ownershipNov 3, 2026Insider tradeSEC
144 · Notice of proposed saleNov 3, 2026Other filingsSEC
10-Q · Quarterly reportNov 3, 2026Quarterly reportSEC
8-K · Current reportNov 3, 2026ResultsSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 2, 2026Other filingsSEC
8-K · Current reportSep 21, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
3 · Initial statement of ownershipSep 18, 2026Insider tradeSEC
8-K · Current reportSep 16, 2026Management or board changeSEC
4 · Change in ownershipSep 3, 2026Insider tradeSEC
144 · Notice of proposed saleSep 3, 2026Other filingsSEC
4 · Change in ownershipSep 1, 2026Insider tradeSEC
144 · Notice of proposed saleSep 1, 2026Other filingsSEC
4 · Change in ownershipAug 17, 2026Insider tradeSEC
144 · Notice of proposed saleAug 17, 2026Other filingsSEC
8-K · Current reportAug 12, 2026Material contractSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
144 · Notice of proposed saleAug 3, 2026Other filingsSEC
8-K/A · Current report, amendedAug 3, 2026Management or board changeSEC
S-8 · Registration statement for employee plansJul 28, 2026Offer documentSEC
10-Q · Quarterly reportJul 28, 2026Quarterly reportSEC
8-K · Current reportJul 28, 2026ResultsSEC
8-K · Current reportJul 8, 2026Current reportSEC
4 · Change in ownershipJul 6, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
144 · Notice of proposed saleJul 1, 2026Other filingsSEC
8-K · Current reportJun 15, 2026Current reportSEC
4 · Change in ownershipJun 12, 2026Insider tradeSEC
144 · Notice of proposed saleJun 12, 2026Other filingsSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleJun 4, 2026Other filingsSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleJun 1, 2026Other filingsSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4/A · Change in ownership, amendedMay 22, 2026Insider tradeSEC
4/A · Change in ownership, amendedMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
4 · Change in ownershipMay 22, 2026Insider tradeSEC
8-K · Current reportMay 20, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialMay 13, 2026Meeting noticeSEC
8-K · Current reportMay 12, 2026Current reportSEC
10-Q · Quarterly reportMay 5, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026ResultsSEC
4 · Change in ownershipMay 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 4, 2026Other filingsSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
8-K/A · Current report, amendedMay 1, 2026Current reportSEC
144 · Notice of proposed saleMay 1, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeApr 28, 2026Big-stake noticeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 6, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 6, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
144 · Notice of proposed saleApr 6, 2026Other filingsSEC
4 · Change in ownershipApr 1, 2026Insider tradeSEC
144 · Notice of proposed saleApr 1, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementMar 27, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
4 · Change in ownershipMar 4, 2026Insider tradeSEC
144 · Notice of proposed saleMar 3, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
144 · Notice of proposed saleMar 2, 2026Other filingsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
4 · Change in ownershipFeb 25, 2026Insider tradeSEC
10-K · Annual reportFeb 25, 2026Annual reportSEC
8-K · Current reportFeb 25, 2026Management or board changeSEC
8-K · Current reportFeb 25, 2026ResultsSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 12, 2026Acquisition or disposalSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
8-K · Current reportJan 12, 2026ResultsSEC
144 · Notice of proposed saleJan 8, 2026Other filingsSEC
4 · Change in ownershipJan 8, 2026Insider tradeSEC
8-K · Current reportJan 6, 2026Current reportSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
144 · Notice of proposed saleJan 2, 2026Other filingsSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
144 · Notice of proposed saleDec 1, 2025Other filingsSEC
8-K · Current reportNov 19, 2025Material contractSEC
8-K · Current reportNov 12, 2025Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 10, 2025Big-stake noticeSEC
4 · Change in ownershipNov 3, 2025Insider tradeSEC
144 · Notice of proposed saleNov 3, 2025Other filingsSEC
10-Q · Quarterly reportOct 28, 2025Quarterly reportSEC
8-K · Current reportOct 28, 2025ResultsSEC
8-K · Current reportOct 22, 2025ResultsSEC
4 · Change in ownershipOct 15, 2025Insider tradeSEC
144 · Notice of proposed saleOct 15, 2025Other filingsSEC
4 · Change in ownershipOct 10, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 23, 2025Insider tradeSEC
8-K · Current reportSep 12, 2025Material contractSEC
8-K · Current reportSep 12, 2025Management or board changeSEC
8-K · Current reportSep 8, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
S-8 · Registration statement for employee plansJul 29, 2025Offer documentSEC
10-Q · Quarterly reportJul 29, 2025Quarterly reportSEC
8-K · Current reportJul 29, 2025ResultsSEC
8-K · Current reportJul 21, 2025Current reportSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
144 · Notice of proposed saleJun 10, 2025Other filingsSEC
144 · Notice of proposed saleJun 9, 2025Other filingsSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipJun 2, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
8-K · Current reportMay 21, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 13, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialMay 12, 2025Meeting noticeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 28, 2025Big-stake noticeSEC
8-K · Current reportApr 16, 2025Current reportSEC
4 · Change in ownershipApr 14, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 7, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 7, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 7, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 28, 2025Meeting noticeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 28, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 20, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
144 · Notice of proposed saleFeb 13, 2025Other filingsSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Alkermes plc’s releases

Common shares
168,043,540
Fully diluted
168,043,540

Fully diluted

LineShares
Common shares168,043,540

Share count over time

CountShares
Nov 22, 2026168,043,540

Open Cap table

Shareholders

Funds

HolderSharesValueAs of
iShares Core S&P Small-Cap ETF10MUS$526MJun 30, 2026
Vanguard Total Stock Market Index Fund5.3MUS$278MJun 30, 2026
iShares Russell 2000 ETF4.3MUS$226MJun 30, 2026
Vanguard Small-Cap Index Fund3.82MUS$200MJun 30, 2026
Avantis U.S. Small Cap Value ETF3.27MUS$138MMay 31, 2026
First Trust NYSE Arca Biotechnology Index Fund2.28MUS$119MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.27MUS$119MJun 30, 2026
Vanguard Small-Cap Growth Index Fund2.2MUS$115MJun 30, 2026
Vanguard Extended Market Index Fund1.91MUS$100MJun 30, 2026
Fidelity Small Cap Index Fund1.83MUS$89.8MJul 31, 2026
Show 50 holders
HolderSharesValueAs of
Vanguard Capital Opportunity Fund1.72MUS$89.9MJun 30, 2026
State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF1.53MUS$80.1MJun 30, 2026
iShares S&P Small-Cap 600 Growth ETF1.5MUS$78.5MJun 30, 2026
T. Rowe Price Mid-Cap Value Fund, Inc.1.45MUS$76.2MJun 30, 2026
iShares Russell 2000 Growth ETF1.24MUS$64.7MJun 30, 2026
iShares Biotechnology ETF1.15MUS$60.5MJun 30, 2026
Vanguard Tax-Managed Small-Cap Fund1.08MUS$56.4MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund997KUS$52.3MJun 30, 2026
Small Cap Growth Fund993KUS$48.7MJul 31, 2026
State Street(R) SPDR(R) S & P 600(TM) Small Cap Growth ETF947KUS$49.6MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.877KUS$46MJun 30, 2026
Fidelity Extended Market Index Fund848KUS$35.8MMay 31, 2026
Vanguard Russell 2000 Index Fund833KUS$35.2MMay 31, 2026
Schwab U.S. Small-Cap ETF794KUS$33.5MMay 31, 2026
College Retirement Equities Fund - Total Global Stock Account703KUS$36.8MJun 30, 2026
Loomis Sayles Small Cap Growth Fund592KUS$31MJun 30, 2026
U.S. Small Cap Portfolio555KUS$27.2MJul 31, 2026
PRIMECAP Odyssey Aggressive Growth Fund534KUS$26.2MJul 31, 2026
Dimensional U.S. Small Cap ETF512KUS$25.1MJul 31, 2026
Artisan International Small-Mid Fund508KUS$26.6MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.504KUS$26.4MJun 30, 2026
Vanguard S&P Small-Cap 600 Index Fund495KUS$20.9MMay 31, 2026
T. Rowe Price Small-Cap Stock Fund, Inc.487KUS$25.5MJun 30, 2026
Vanguard Health Care Index Fund471KUS$19.9MMay 31, 2026
Schwab U.S. Mid-Cap ETF446KUS$18.8MMay 31, 2026
Fidelity Small Cap Growth Fund436KUS$21.4MJul 31, 2026
Schwab Small-Cap Index Fund407KUS$20MJul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund395KUS$20.7MJun 30, 2026
Nuveen Quant Small Cap Equity Fund377KUS$18.5MJul 31, 2026
BlackRock Advantage Small Cap Core Fund357KUS$15.1MMay 29, 2026
iShares Russell 2000 Value ETF317KUS$16.6MJun 30, 2026
Small Cap Equity Portfolio317KUS$15.5MJul 31, 2026
Franklin Small Cap Growth Fund314KUS$15.4MJul 31, 2026
Fidelity Total Market Index Fund312KUS$13.2MMay 31, 2026
U.S. Micro Cap Portfolio311KUS$15.2MJul 31, 2026
Master Small Cap Index Series309KUS$16.2MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF290KUS$14.2MJul 31, 2026
Dimensional U.S. Targeted Value ETF284KUS$13.9MJul 31, 2026
iShares U.S. Small-Cap Equity Factor ETF261KUS$12.8MJul 31, 2026
JNL Small Cap Index Fund260KUS$13.6MJun 30, 2026

This page holds 50 of 442 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,035USD 46.17US$93,956Nov 3, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 41.03US$83,455Oct 2, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 48.01US$97,652Sep 3, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale9,000USD 46.99US$423KSep 1, 2026
Nichols Christian Todd
Officer: SVP, Chief Commercial Officer
Sale6,912USD 49.19US$340KAug 17, 2026
Nichols Christian Todd
Officer: SVP, Chief Commercial Officer
Sale664USD 49.65US$32,968Aug 17, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 48.58US$98,812Aug 3, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale9,000USD 48.58US$437KAug 3, 2026
snyderman nancy lynn MD
Director
Sale44,472USD 50.35US$2.24MAug 3, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 54.03US$110KJul 6, 2026
All 20 trades
TradeTradeSharesPriceValueDate
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale8,300USD 51.46US$427KJul 1, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale700USD 52.13US$36,491Jul 1, 2026
Wright Christopher I
Director
Sale2,000USD 45.10US$90,200Jun 12, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 43.05US$87,564Jun 4, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale9,000USD 41.67US$375KJun 1, 2026
Parisi Samuel Joseph
Officer: VP, Finance (Interim PAO)
Sale16,217USD 42.36US$687KMay 29, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 33.20US$67,529May 4, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale9,000USD 33.40US$301KMay 1, 2026
Gaffin David Joseph
Officer: EVP, CLO, Alkermes, Inc.
Sale2,034USD 34.57US$70,315Apr 6, 2026
Hopkinson Craig C.
Officer: EVP R&D, Chief Medical Officer
Sale9,000USD 35.51US$320KApr 1, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Wendy L Dixon
Other companies: Zevra Therapeutics, Inc. (Director · Since at least Apr 25, 2023); Iovance Biotherapeutics, Inc. (Director · Jun 10, 2022 – Jun 10, 2022 · Past); Black Diamond Therapeutics, Inc. (Director · Apr 6, 2022 – Mar 15, 2024 · Past); Arvinas, Inc. (Director · Jun 29, 2020 – Jun 15, 2023 · Past); Sesen Bio Inc (Director · Jun 12, 2018 – Jun 19, 2019 · Past); Voyager Therapeutics, Inc. (Director · Jan 1, 2017 – Jun 4, 2020 · Past); Eleven Biotherapeutics Inc (Director · Oct 22, 2014 – May 19, 2017 · Past); Bluebird bio Inc (Director · Jun 18, 2013 – Nov 11, 2021 · Past); Ardea Biosciences Inc (Director · Apr 6, 2011 – Jun 19, 2012 · Past); Furiex Pharmaceuticals Inc (Director · May 27, 2010 – Jul 2, 2014 · Past); Incyte Corporation (Director · May 21, 2010 – Mar 31, 2022 · Past); Orexigen Therapeutics Inc (Director · Apr 20, 2010 – Jun 9, 2015 · Past); Dentsply Sirona Inc. (Director · Jul 31, 2007 – Jul 8, 2010 · Past); Bristol-Myers Squibb Company (CMO & Pres, Global Marketing · Mar 7, 2006 – May 22, 2006 · Past)
Director · Jan 13, 2011 – Jun 14, 2022 · Past
Paul Schimmel
Other companies: aTyr Pharma, Inc. (Director · Since at least May 6, 2015); Alnylam Pharmaceuticals, Inc. (Co-founder and member of the Board of Directors · Since at least Jan 31, 2006); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Sirtris Pharmaceuticals Inc (Director · May 22, 2007 – Nov 30, 2007 · Past); Repligen Corporation (Director · Aug 11, 2006 – Jun 14, 2007 · Past)
Director · Mar 2, 2006 – Jun 15, 2007 · Past
Frank A. Wilson
Other companies: Novanta Inc. (Member of Board of Directors · Since at least May 13, 2021); Cabot Corporation (Director · Since at least Sep 13, 2018); Sparton Corporation (Director · Mar 4, 2019 – Mar 4, 2019 · Past); Revvity, Inc. (Please See Remarks · Dec 7, 2017 – Mar 5, 2018 · Past)
Director · Since at least Sep 12, 2019
James A Robinson Jr
Other companies: Eledon Pharmaceuticals, Inc. (Director · Since at least Oct 1, 2023); UroGen Pharma Ltd. (Director · Since at least Jul 25, 2023); Urovant Sciences Ltd (PEO;CEO/Urovant Sciences, Inc., Director · Mar 1, 2019 – Mar 29, 2021 · Past); Neos Therapeutics Inc (Director · Jan 29, 2019 – Mar 19, 2021 · Past)
President & COO,Alkermes, Inc. · Mar 5, 2018 – Apr 4, 2019 · Past
Joshua Reed
Other companies: Scholar Rock Holding Corporation (Director · Since at least Mar 16, 2021); Omega Therapeutics Inc (Chief Financial Officer · May 23, 2022 – Feb 7, 2024 · Past); Aldeyra Therapeutics, Inc. (Chief Financial Officer · Jul 30, 2018 – Mar 30, 2022 · Past)
SVP, Chief Financial Officer · Since at least Sep 12, 2025
Nancy L. Snyderman
Other companies: Lyra Therapeutics, Inc. (Board Director · Since at least Oct 27, 2020); Future Health Esg Corp (Director · Sep 9, 2021 – Oct 24, 2021 · Past); Axonics Modulation Technologies Inc (Director · Apr 8, 2019 – Aug 24, 2020 · Past)
Director · Since at least May 23, 2018
Nancy S. Lurker
Other companies: Collegium Pharmaceutical, Inc. (Director · Since at least Feb 4, 2025); EyePoint, Inc. (Director · Since at least Mar 29, 2019); Aquestive Therapeutics, Inc. (Director · Jun 13, 2019 – Jun 15, 2021 · Past)
Director · Since at least Mar 5, 2024
Richard F. Pops
Other companies: Neurocrine Biosciences, Inc. (Director · Since at least May 28, 2015); Acceleron Pharma Inc (Director · Mar 3, 2016 – Jan 25, 2019 · Past); Epizyme Inc (Director · Jul 8, 2015 – May 29, 2020 · Past)
Director · Since at least Sep 10, 2015
James M. Frates
Other companies: Amylyx Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Jan 6, 2022); Sage Therapeutics Inc (Director · Since at least Jul 17, 2014)
SVP, Alks Inc; CFO ALKS · May 2, 2006 – May 14, 2020 · Past
Shane M. Cooke
Other companies: Prothena Corporation plc (Director · Since at least May 16, 2018); Endo International PLC (Director · Jun 8, 2018 – Jun 11, 2021 · Past)
Director · Since at least Jan 11, 2018
All 40 people
PersonSeat
Brian P. McKeon
Other companies: Dentsply Sirona Inc. (Director · Since at least Feb 24, 2026)
Director · Since at least Aug 18, 2025
Craig Hopkinson
Other companies: Albireo Pharma Inc (Director · Dec 1, 2022 – Mar 2, 2023 · Past)
Executive Vice President, Research & Development and Chief Medical Officer · Since at least Jun 7, 2019
Emily Peterson Alva
Other companies: Amneal Pharmaceuticals, Inc. (Director · May 4, 2018 – May 5, 2025 · Past)
Director · May 18, 2021 – Jun 29, 2024 · Past
Michael J Landine
Other companies: Kopin Corporation (Director · May 11, 2012 – May 9, 2018 · Past)
SVP, Corp Dev., Alkermes, Inc. · Oct 3, 2011 – Feb 23, 2024 · Past
Richard B. Gaynor
Other companies: Zai Lab Ltd. (Director · Since at least Nov 19, 2021)
Director · Since at least Dec 2, 2020
Andy WilsonDirector · Since at least Feb 25, 2026
Anne C. WhitakerDirector · Since at least Sep 16, 2026
Anne GiovanoniSenior Vice President, Corporate Counsel and Secretary · Since at least Nov 5, 2026
Bhaskar RegeSenior Vice President, Discovery Medicine & Pharmaceutical Sciences · Since at least Nov 5, 2026
Blair JacksonChief Executive Officer · Since at least Jan 11, 2021
Cato T. LaurencinDirector · Since at least May 21, 2026
Christopher I. Wright M.D.Director · Since at least May 21, 2026
David Angelo Daglio JrDirector · Dec 9, 2020 – Jun 29, 2024 · Past
David GaffinEVP, CLO, Alkermes, Inc. · Since at least Feb 16, 2021
Declan O’ConnorSenior Vice President, Operations and Environment, Health and Safety (EHS) · Since at least Nov 5, 2026
Drew SansoneSenior Vice President, Regulatory Affairs · Since at least Nov 5, 2026
Elliot EhrichEVP, R&D & CMO, Alkermes, Inc. · May 17, 2010 – May 28, 2017 · Past
Gordon G PughSVP, COO & CRO, Alkermes, Inc. · Sep 21, 2006 – Dec 31, 2016 · Past
James SchoenerSenior Vice President, Business Development and Alliance Management · Since at least Nov 5, 2026
Jamie ConstantineInvestor Relations · Since at least Jul 14, 2026
Julie Lekstrom HimesSenior Vice President, Clinical Development · Since at least Oct 13, 2026
Kanchan RelwaniSenior Vice President, Medical Affairs · Since at least Apr 30, 2025
Paul J MitchellDirector · Sep 21, 2006 – May 20, 2021 · Past
Peter NormanSenior Vice President, Policy, Government & Community Relations · Since at least Nov 5, 2026
Robert A BreyerDirector · Oct 5, 2011 – May 20, 2021 · Past
Samuel Joseph ParisiVP, Finance (Interim PAO) · Since at least May 29, 2026
Sandy CoombsInvestor Relations · Since at least Apr 21, 2026
Stephen SchiavoSenior Vice President, Chief Human Resources Officer · Since at least Nov 5, 2026
Todd NicholsSenior Vice President, Chief Commercial Officer · Since at least Nov 5, 2026
Tom SkoffSenior Vice President, Chief Information Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Alkermes plc.